DEER PARK, Ill. , Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C.

Product sales and royalty revenue of $9.1 million , representing 40% growth over Q2 2023 and the 14 th straight quarter of sequential product sales growth New drug application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA) and assigned a February 28, 2025 PDUFA date Q2

DEER PARK, Ill. , July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial

- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill. , July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on

•  Q1 2024 revenue of $8.0 million , representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth •  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400 •  Management to hold conference call

DEER PARK, Ill. , May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen , Chief Executive Officer, and James Gruber , Chief

- Company anticipates 10-month review for potential approval in Q1 2025 - - Eton expects ET-400 and Alkindi Sprinkle ® to achieve potential combined peak sales of more than $50 million annually - - Product has patent protection through 2043 - DEER PARK, Ill.

DEER PARK, Ill. , April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales of more than $10 million annually U.S.

Q4 2023 revenue of $7.3 million , representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth Full year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million , a 132% increase from 2022 Announced